Retinoic Acid (Tretinoin) #38255
Product Information
Product Usage Information
Retinoic Acid (Tretinoin) is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.11 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Product Description
| Molecular Weight | 300.4 g/mol |
| Purity | >98% |
| Molecular Formula | C20H28O2 |
| CAS | 302-79-4 |
| Solubility | Soluble in DMSO at 25 mg/mL or ethanol at 10 mg/mL. |
Background
The ligand Retinoic Acid (Tretinoin) binds retinoic acid receptors (RARα, RARβ, and RARγ) and retinoid X receptors (RXRα, RXRβ, and RXRγ). RAR-RXR heterodimers and RXR homodimers control gene expression by binding to specific Retinoic Acid response elements, by recruiting cofactors and the transcriptional machinery, and by indirectly regulating chromatin structure (1). Signaling pathways controlled by Retinoic Acid coordinate cell proliferation, differentiation, apoptosis, and development of many organs and tissues (2). Oxidation of vitamin A creates a retinal intermediate which is subsequently oxidized to form Retinoic Acid (3). All-trans retinoic acid (ATRA) is an active metabolite of vitamin A that is used in the treatment of several cancers, including ovarian carcinoma, bladder cancer, neuroblastoma, and Kaposi's sarcoma. ATRA inhibits inflammation in rheumatoid arthritis and inhibits proliferation in vascular smooth muscle cells (4). A topical version of Retinoic Acid (Tretinoin) has long been used to treat acne and the effects of photoaging of the skin (5).
- Leid, M. et al. (1992) Trends Biochem Sci 17, 427-33.
- Ghyselinck, N.B. and Duester, G. (2019) Development 146, dev167502. doi: 10.1242/dev.167502.
- Kam, R.K. et al. (2012) Cell Biosci 2, 11.
- Siddikuzzaman et al. (2011) Immunopharmacol Immunotoxicol 33, 241-9.
- Szymański, Ł. et al. (2020) Cells 9, 2660. doi: 10.3390/cells9122660.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.